RAPTRAPT Therapeutics, Inc.

Nasdaq rapt.com


$ 2.88 $ -0.16 (-5.25 %)    

Thursday, 27-Jun-2024 15:59:55 EDT
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 2.89
$ 3.08
$ 0.00 x 0
$ 0.00 x 0
$ 2.88 - $ 3.09
$ 2.88 - $ 27.35
215,479
na
111.63M
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-11-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 12-11-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wolfe-research-downgrades-rapt-therapeutics-to-peer-perform

Wolfe Research analyst Andy Chen downgrades RAPT Therapeutics (NASDAQ:RAPT) from Outperform to Peer Perform.

 barclays-downgrades-rapt-therapeutics-to-equal-weight-lowers-price-target-to-4

Barclays analyst Leon Wang downgrades RAPT Therapeutics (NASDAQ:RAPT) from Overweight to Equal-Weight and lowers the price t...

 guggenheim-downgrades-rapt-therapeutics-to-neutral

Guggenheim analyst Yatin Suneja downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral.

 whats-going-on-with-dermatitis-focused-rapt-therapeutics-stock-on-thursday

RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to li...

 rapt-therapeutics-q1-eps-079-beats-081-estimate

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-reiterates-neutral-on-rapt-therapeutics

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.

 rapt-therapeutics-highlights-results-from-phase-2-trial-of-tivumecirnon-in-combination-with-anti-pd-1-immunotherapy-in-cpi-experienced-head-and-neck-cancer-patients

- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% i...

 jp-morgan-maintains-neutral-on-rapt-therapeutics-lowers-price-target-to-13

JP Morgan analyst Anupam Rama maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and lowers the price target from $15 ...

 rapt-therapeutics-q4-eps-080-beats-086-estimate-cash-balance-of-1589m-as-of-december-31-2023

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0...

 rapt-therapeutics-announces-multiple-late-breaking-presentations-at-the-upcoming-american-association-for-cancer-research-annual-meeting

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developi...

 ubs-downgrades-rapt-therapeutics-to-neutral-lowers-price-target-to-10

UBS analyst Eliana Merle downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral and lowers the price target from $61...

 rivian-automotive-reports-q4-loss-joins-etsy-lucid-group-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday.

 whats-going-on-with-rapt-therapeutics-stock-on-wednesday

Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma...

 why-international-flavors--fragrances-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported m...